(NYSE: ADCT) Adc Therapeutics Sa's forecast annual revenue growth rate of 50.81% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.28%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.1%.
Adc Therapeutics Sa's revenue in 2026 is $79,175,000.On average, 8 Wall Street analysts forecast ADCT's revenue for 2026 to be $9,942,532,821, with the lowest ADCT revenue forecast at $8,662,989,771, and the highest ADCT revenue forecast at $11,742,414,898. On average, 7 Wall Street analysts forecast ADCT's revenue for 2027 to be $16,814,671,088, with the lowest ADCT revenue forecast at $14,609,176,408, and the highest ADCT revenue forecast at $18,777,230,656.
In 2028, ADCT is forecast to generate $36,767,148,043 in revenue, with the lowest revenue forecast at $28,046,922,251 and the highest revenue forecast at $49,947,967,747.